CASP3 and cancer: In contrast to HCT116, DLD-1 and RKO cancer cells, the same combination of rosiglitazone and LA-12 did not exert any apoptosis-inducing potential in NCM460 cells, as evidenced by the absence of PARP cleavage (S6A Fig) and caspase-3 activation (S6B Fig).